The Role of PARP Inhibitors in Advanced Prostate Cancer Webcast (2023)

Based on the documented need from the most recent AUA needs assessment in advanced prostate cancer, this symposium will address the role of PARP Inhibitor treatment, as well as evidence and outcomes of PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/SUO Guideline. 


This educational activity is supported by an independent educational grant from:

  • Pfizer, Inc.

Target Audience

  • Urologists
  • Residents
  • APPs

Learning Objectives

At the conclusion of this activity, participants will be able to:  

  1. Review recommended criteria for genetic testing of prostate cancer patients and how to interpret these tests.
  2. Explain the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment.
  3. Describe the role of PARP Inhibitor treatment alone and in combination with androgen receptor targeted therapies.
  4. Review the evidence and outcomes on PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/SUO Guideline.
  5. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Davis, Nancy B.AstraZenecaScientific Study or TrialCurrent
Davis, Nancy B.Hoffman-LaRocheScientific Study or TrialCurrent
Davis, Nancy B.PfizerScientific Study or TrialCurrent
Davis, Nancy B.MerckScientific Study or TrialCurrent
Davis, Nancy B.IncyteScientific Study or Trial05/21/2021
Davis, Nancy B.Mirati TherapeuticsScientific Study or Trial11/10/2022
Davis, Nancy B.Calithera BiosciencesScientific Study or TrialCurrent
Davis, Nancy B.Taris BiomedicalScientific Study or Trial12/31/2021
Davis, Nancy B.ImmunomedicsScientific Study or TrialCurrent
Davis, Nancy B.Bristol Myers SquibbScientific Study or TrialCurrent
Davis, Nancy B.JanssenConsultant or AdvisorCurrent
Davis, Nancy B.GileadScientific Study or TrialCurrent
Davis, Nancy B.ExelixisScientific Study or TrialCurrent
Ross, Ashley E.GenomeDx BiosciencesConsultant or AdvisorCurrent
Ross, Ashley E.JanssenConsultant or AdvisorCurrent
Ross, Ashley E.PfizerConsultant or AdvisorCurrent
Ross, Ashley E.Blue EarthConsultant or AdvisorCurrent
Ross, Ashley E.TempusConsultant or AdvisorCurrent
Ross, Ashley E.BayerConsultant or AdvisorCurrent
Ross, Ashley E.MyovantConsultant or AdvisorCurrent
Ross, Ashley E.AstellasConsultant or AdvisorCurrent
Ross, Ashley E.VeracyteConsultant or AdvisorCurrent
Ross, Ashley E.LantheusConsultant or AdvisorCurrent
Scarpato, Kristen R.None  


PDF icon Education Council Disclosures_2022.pdf


PDF iconCOI Review Work Group Disclosures_2023_0.pdf


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.


Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 1.5 hours

Release Date: May, 2023
Expiration Date: May, 2024


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.